BVF as of June 30, 2017
Portfolio Holdings for BVF
BVF holds 34 positions in its portfolio as reported in the June 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 12.5 | $81M | 1.6M | 50.67 | |
| Chemocentryx | 12.0 | $77M | 8.2M | 9.36 | |
| Array BioPharma | 7.9 | $51M | 6.1M | 8.37 | |
| Anaptysbio Inc Common (ANAB) | 6.2 | $40M | 1.7M | 23.93 | |
| Loxo Oncology | 5.8 | $37M | 463k | 80.19 | |
| Glycomimetics (GLYC) | 5.2 | $33M | 3.0M | 11.16 | |
| Cytomx Therapeutics (CTMX) | 4.9 | $31M | 2.0M | 15.50 | |
| Cti Biopharma | 4.4 | $29M | 8.6M | 3.31 | |
| Forward Pharma A/s | 4.4 | $28M | 1.4M | 20.33 | |
| Concert Pharmaceuticals I equity | 4.0 | $26M | 1.9M | 13.95 | |
| Cytokinetics (CYTK) | 3.7 | $24M | 2.0M | 12.10 | |
| Pieris Pharmaceuticals (PIRS) | 2.7 | $18M | 3.5M | 5.06 | |
| Achillion Pharmaceuticals | 2.5 | $16M | 3.5M | 4.59 | |
| Tocagen | 2.4 | $15M | 1.3M | 12.03 | |
| Biolinerx Ltd-spons | 2.3 | $15M | 18M | 0.85 | |
| Oncomed Pharmaceuticals | 2.3 | $15M | 4.4M | 3.33 | |
| Infinity Pharmaceuticals (INFIQ) | 1.9 | $12M | 7.9M | 1.57 | |
| Cascadian Therapeutics | 1.8 | $12M | 3.1M | 3.72 | |
| Xenon Pharmaceuticals (XENE) | 1.7 | $11M | 3.5M | 3.15 | |
| Xoma Corp Del (XOMA) | 1.6 | $11M | 1.5M | 6.99 | |
| ArQule | 1.4 | $9.2M | 7.4M | 1.24 | |
| Spring Bk Pharmaceuticals In | 1.3 | $8.3M | 615k | 13.54 | |
| Ignyta | 1.1 | $7.2M | 700k | 10.35 | |
| Nivalis Therapeutics | 1.0 | $6.4M | 2.6M | 2.41 | |
| Gtx Inc Del | 0.9 | $5.9M | 1.1M | 5.29 | |
| Orexigen Therapeutics Inc. 144a 2 3/4% Due 12/1/2020 Jd1 note 2.750%12/0 | 0.8 | $5.0M | 10M | 0.50 | |
| Sunesis Pharmaceuticals Inc Ne | 0.7 | $4.8M | 1.8M | 2.70 | |
| Aduro Biotech | 0.5 | $3.4M | 300k | 11.40 | |
| Corvus Pharmaceuticals (CRVS) | 0.5 | $3.3M | 274k | 12.10 | |
| Regulus Therapeutics | 0.5 | $3.2M | 3.3M | 0.99 | |
| Orexigen Therapeutics | 0.3 | $2.1M | 735k | 2.90 | |
| Anthera Pharmaceuticals (ANTH) | 0.2 | $1.6M | 1.0M | 1.62 | |
| Pain Therapeutics | 0.2 | $1.3M | 326k | 4.12 | |
| Fate Therapeutics (FATE) | 0.2 | $1.3M | 391k | 3.24 |
